TIS21/BTG2 inhibits breast cancer growth and progression by differential regulation of mTORc1 and mTORc2-AKT1-NFAT1-PHLPP2 signaling axis.

CONCLUSIONS: TIS21/BTG2 significantly lost in the infiltrating ductal carcinoma, but it can inhibit cancer growth via the TIS21/BTG2-tsc1/2-mTORc1-p70S6K axis and downregulate cancer progression via the TIS21/BTG2-mTORc2-AKT1-NFAT1-PHLPP2 pathway.
PMID: 29808317 [PubMed - indexed for MEDLINE]

Source: Clinical Breast Cancer - August 1, 2018 Category: Cancer & Oncology Authors: Sundaramoorthy S, Devanand P, Ryu MS, Song KY, Noh DY, Lim IK Tags: J Cancer Res Clin Oncol Source Type: research